Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures.

Autor: Mangion M; Département de génie chimique, Université Laval, Québec, QC, Canada., Gélinas JF; Department of Bioengineering, McGill University, Montreal, QC, Canada., Bakhshi Zadeh Gashti A; Département de génie chimique, Université Laval, Québec, QC, Canada., Azizi H; Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Université Laval, Quebec, QC, Canada., Kiesslich S; Department of Bioengineering, McGill University, Montreal, QC, Canada., Nassoury N; Human Health Therapeutics, National Research Council Canada, Montreal, QC, Canada., Chahal PS; Human Health Therapeutics, National Research Council Canada, Montreal, QC, Canada., Kobinger G; Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de Québec, Université Laval, Quebec, QC, Canada., Gilbert R; Human Health Therapeutics, National Research Council Canada, Montreal, QC, Canada., Garnier A; Département de génie chimique, Université Laval, Québec, QC, Canada., Gaillet B; Département de génie chimique, Université Laval, Québec, QC, Canada., Kamen A; Department of Bioengineering, McGill University, Montreal, QC, Canada. Electronic address: amine.kamen@mcgill.ca.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2020 Nov 25; Vol. 38 (50), pp. 7949-7955. Date of Electronic Publication: 2020 Nov 01.
DOI: 10.1016/j.vaccine.2020.10.058
Abstrakt: Acquired Immune Deficiency Syndrome (AIDS) in humans is a result of the destruction of the immune system caused by Human Immunodeficiency Virus (HIV) infection. This serious epidemic is still progressing world-wide. Despite advances in treatment, a safe and effective preventive HIV vaccine is desired to combat this disease, and to save millions of lives. However, such a vaccine is not available yet although extensive amounts of resources in research and development have been invested over three decades. In light of the recently approved Ebola virus disease vaccine based on a recombinant vesicular stomatitis virus (rVSV-ZEBOV), we present the results of our work on three novel VSV-vectored HIV vaccine candidates. We describe the design, rescue, production and purification method and evaluate their immunogenicity in mice prior to preclinical studies that will be performed in non-human primates. The production of each of the three candidate vaccines (rVSV-B6-NL4.3Env/SIVtm, rVSV-B6-NL4.3Env/Ebtm and rVSV-B6-A74Env(PN6)/SIVtm) was evaluated in small scale in Vero cells and it was found that production kinetics on Vero cells vary depending on the HIV gp surface protein used. Purified virus preparations complied with the WHO restrictions for the residual DNA and host cell protein contents. Finally, when administered to mice, all three rVSV-HIV vaccine candidates induced an HIV gp140-specific antibody response.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Crown Copyright © 2020. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: